Sources of finance for commercialization Sample Clauses

Sources of finance for commercialization. The first big customers to take up the system if it works well are the two participating end- user organizations ORBIS and MRPS. Both are working close with insurance companies for the provision of elderly homecare. Already ORBIS is chosen by CZ, a big insurance company, as the Living Lab to test eHealth solutions. In this role ORBIS will in cooperation with CZ implement eHealth solutions and test them via a model developed by CZ and ORBIS together. In this model research for the eHealth solutions will be done for patient satisfaction, the care paths, clinical efficacy, organisational and care costs. For the eHealth solutions which have good outcomes based on this research, CZ will look for structural financing via the insurance. If Miraculous-Life is successful this can also be further tested via living lab cooperation between ORBIS and CZ. This can be a starting point of stimulating other insurances in other European countries in allocating budget for introducing the system in the elderly care process. The assumption that other organizations will be willing to invest in these developments, is also supported by findings of other projects in this area. Examples:  FlevoMind/Connected Vitality Network, a network aiming at remote support of elderly and psychiatric patients, was supported by CMO (‘Centre for social development’ in Flevoland, the Netherlands).  Xxxxxxx, a virtual assistant (avatar) for agenda control (reminders of meetings and medicine), control of home automation, video calling with caregivers or relatives, etc., is supported by the province of Gelderland and the city of Deventer (both in the Netherlands).  GoOV is an app for assistance in using public transport. Local communities provide funding so that their citizens can get access to this tool.  Insurance company CZ has invested in care robot ‘Rose’, also in the Netherlands. This insurance company has dedicated funding (‘CZ Fonds’) for supporting such initiatives.  In the Netherlands it is becoming more common that the government or insurance companies pay for automation technology that enables elderly to live independently. Solutions such as a robotic arm or fall detection can even be part of the basic insurance if there is a medical indication22.  In Germany the most important deciding factor is the listing in the official aid catalogue (Hilfsmittelkatalog) of care insurance companies that is followed by all public insurers. In the last years various technical systems have been adde...
Sample 1Sample 2
AutoNDA by SimpleDocs
Sources of finance for commercialization. In case of a successful trial’s outcome the first big customers to take up the system are the two participating end-user organizations ORBIS and MRPS. Those two are working close with insurance companies for the provision of elderly homecare. Already ORBIS, through its participation in other innovative research initiatives, has managed to achieve that a 3% (3.5 million Euro for 2013) of the yearly budget allocated from CZ, the biggest Insurance companies in the Netherlands, to ORBIS to be used for carrying out research in the introduction of innovative technologies in elderly care reducing thus care cost in the next years. CZ has already agreed that in case of a successful Miraculous-Life trial a financial plan will be put in place for having the system being commercialized and taken up in the ORBIS homecare provision setup. This can be a starting point of stimulating positively other insurances in other European countries in allocating budget for introducing the system in the elderly care process
Sample 1
Sources of finance for commercialization. For each country represented by at least one partner within the project a list of organizations that may be interested in making use of the project outcome will be prepared. We will also investigate what the possibilities for funding for example by insurance companies can be. In case of a successful trial’s outcome, and provided the system meets the needs of residents, the first big customers to take up the system are the two participating end-user organizations ORBIS and MRPS. Those two are working close with insurance companies for the provision of elderly homecare. Already ORBIS, through its participation in other innovative research initiatives, has managed to achieve that a 3% (3.5 million Euro for 2013) of the yearly budget allocated from CZ, one of the biggest insurance companies in the Netherlands, to ORBIS to be used for carrying out research in the introduction of innovative technologies in elderly care reducing thus care cost in the next years. CZ has already agreed that in case of a successful Miraculous-Life trial a financial plan will be put in place for having the system being commercialized and taken up in the ORBIS homecare provision set-up. This can be a starting point of stimulating other insurances in other European countries in allocating budget for introducing the system in the elderly care process. The assumption that other organizations will be willing to invest in these developments, is also supported by findings of similar projects. Examples:  FlevoMind/Connected Vitality Network, a network aiming at remote support of elderly and psychiatric patients, was supported by CMO (‘Centre for social development in Flevoland, the Netherlands).  Xxxxxxx, a virtual assistant (avatar) for agenda control (reminders of meetings and medicine), control of home automation, video calling with caregivers or relatives, etc., is supported by the province of Gelderland and the city of Deventer (both in the Netherlands).  GoOV is an app for assistance in using public transport. Local communities provide funding so that their citizens can get access to this tool.  Insurance company CZ has invested in care robot ‘Rose’, also in the Netherlands.
Sample 1

Related to Sources of finance for commercialization

  • Commercialization Plan At such times as the JGC will deem appropriate, the JGC will direct the Parties to mutually prepare a Worldwide Commercialization Plan, and the JGC will review and approve such initial Worldwide Commercialization Plan. Thereafter, the JGC will have one or the other Party (or both) update the Worldwide Commercialization Plan each calendar year, and the JGC will review and approve any such update or any other amendment to the Worldwide Commercialization Plan. Notwithstanding anything in this CCPS Agreement to the contrary, the Parties acknowledge and agree that (i) Bluebird may decline to perform any Commercialization activity proposed to be conducted by Bluebird in the Worldwide Commercialization Plan (other than Manufacturing of Vectors and associated Payloads), and (ii) the Worldwide Commercialization Plan will not include, and Bluebird will have no obligation to perform, any such Commercialization activity that Bluebird has declined to perform, provided that once Bluebird has agreed to perform a Commercialization activity, it will be obligated to perform, and cannot decline to perform, such activity. In addition, either Party may request at any time that the JGC consider and approve other updates to the Worldwide Commercialization Plan. Further: (a) The JGC will set the required form and contents of the Worldwide Commercialization Plan. The Worldwide Commercialization Plan will reflect a singular marketing and sales approach worldwide, and will specify, among other things, the number of sales reps in the U.S. for each Party, allocation of regions in the U.S. for each Parties’ sales force, creation of marketing materials, planning for conferences, and other marketing activities. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. (b) Neither Party (itself or by or through any others, including any Affiliates or Sublicensees) will take any material action regarding the Commercialization of Licensed Product unless described in the Worldwide Commercialization Plan or approved by the JGC. (c) All Commercialization of Licensed Product for U.S. Administration will be conducted under the supervision of the JGC and as part of the U.S. Development & Commercialization Program. (d) Celgene will have final decision making authority for all Commercialization activities worldwide, including timing of launch and pricing and the Worldwide Development Plan.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Concession Area, including its abandonment.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Technology Research Analyst Job# 1810 General Characteristics

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones) B. Estimated total development time

  • Joint Commercialization Committee (i) The JCC shall oversee Commercialization of JAK Licensed Products in the Field worldwide. As soon as practicable following the Effective Date (but in no event more than thirty (30) days following the Effective Date), each Party shall designate its initial three (3) representatives on the JCC. The JCC shall be composed of appropriate and key executives of Novartis together with an equal number of appropriate and key executives from Incyte. Novartis and Incyte shall each appoint a person from among its representatives on the JCC to serve as the co-chairperson of the JCC. The co-chairpersons shall not have any greater authority than any other representative on the JCC and shall conduct the following activities of the JCC: (A) calling meetings of the JCC; (B) preparing and issuing minutes of each such meeting within thirty (30) days thereafter; (C) preparing and circulating an agenda for the upcoming meeting; and (D) ensuring that any decision-making delegated to the JCC is carried out in accordance with Section 3.5. (ii) The JCC shall be responsible for: (A) overseeing, reviewing and coordinating the Commercialization of JAK Licensed Products in the Field worldwide; (B) developing and overseeing the Global Branding Strategy; (C) setting overall strategic objectives and plans related to Commercialization of JAK Licensed Products in the Field worldwide; (D) reviewing, commenting on and approving the Promotional Plan; (E) reviewing Commercialization issues for JAK Licensed Products in the Field in the Novartis Territory that will have an impact on Commercialization of JAK Licensed Products in the Field in the Incyte Territory; (F) reviewing Commercialization issues for JAK Licensed Products in the Field in the Incyte Territory that will have an impact on Commercialization of JAK Licensed Products in the Field in the Novartis Territory; (G) providing a forum for the Parties to discuss the Commercialization of JAK Licensed Products in the Field worldwide; and (H) such other responsibilities as may be assigned to the JCC pursuant to this Agreement or as may be mutually agreed upon by the Parties from time to time.

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Marketing Plan The MCOP shall submit an annual marketing plan to ODM including all planned activities for promoting membership in or increasing awareness of the MCOP. The marketing plan submission shall include an attestation by the MCOP that the plan is accurate and is not intended to mislead, confuse, or defraud the eligible individuals or ODM.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!